Acute and chronic diseases of the airways that reside with sticky mucus secretion and hinder its expectoration.
Composition:
5 ml of syrup contains 15 mg Ambroxol hydrochloride. The preparation contains: methyl parahydroxybenzoate, propyl parahydroxybenzoate, propylene glycol.
Action:
Drug with secretolytic and secretomotor action. Ambroxol is the active metabolite of bromohexine. It increases the production of surfactant in the lungs and stimulates the activity of the ciliary epithelium of the respiratory system. As a result, the amount of mucus increases and its transport is improved. Increased mucus secretion and mucociliary clearance facilitates expectoration. After oral administration, they are quickly and almost completely absorbed from the gastrointestinal tract, the maximum concentration in blood reaches after about 0.5-3 h. Ambroxol is bound to plasma proteins in about 90%. Metabolism occurs mainly in the liver. 90% of the dose is excreted in the urine.
Contraindications:
Hypersensitivity to the components of the preparation.
Precautions:
Use with caution in patients with severe hepatic impairment or with impaired renal function. In severe renal failure there is a risk of accumulation of ambroxol metabolites that are formed in the liver. Due to the risk of severe skin reactions (very rarely) in the case of new lesions on the skin or mucous membranes, the patient should discontinue the use of the drug and immediately report to the doctor. Carefully use in patients with mucocutaneous transport disorders in the bronchi and a large amount of secretion (eg in a rare syndrome of immobile cilia) and in patients with peptic ulcer disease and / or duodenum (risk of damage to the gastric mucosa). It is not recommended for use in children in the 1st year of age. The preparation contains sorbitol - should not be used in patients with rare hereditary problems of fructose intolerance; the preparation may have a slight laxative effect. The preparation contains methyl and propyl parahydroxybenzoates, which may cause allergic reactions (possible late-type reactions). The syrup contains propylene glycol, which can cause symptoms like after drinking alcohol.
Pregnancy and lactation:
Ambroxol hydrochloride crosses the placental barrier. The extensive clinical experience with use after the 28th week of pregnancy did not reveal a harmful effect on the fetus. However, ordinary precautions should be taken when using the drug during pregnancy. Use in the first trimester of pregnancy is not recommended. Ambroxol hydrochloride is excreted in breast milk. Although no adverse effects are expected on breastfed infants, ambroxol is not recommended in breast-feeding women.
Side effects:
Common: dysgeusia, nausea, hypoesthesia (weakness of sensation) in the mouth and throat. Uncommon: dry mouth, vomiting, diarrhea, dyspepsia, abdominal pain. Rare: skin rash, urticaria. Very rare: severe skin reactions, such as Stevens-Johnson syndrome, epidermal necrolysis. Not known: throat dryness, anaphylactic reactions including anaphylactic shock, angioneurotic edema, pruritus and other signs of hypersensitivity.
Dosage:
Orally. Adults and children over 12 years: acute treatment or initial treatment for chronic diseases should be started with a dose of: 60 mg (20 ml) twice daily for the first 2-3 days, then the dose can be reduced to 30 mg (10 ml) 2 times a day. The maximum daily dose is 120 mg. Children 6-12 years: 15 mg (5 ml) 2-3 times a day; 2-6 years: 7.5 mg (2.5 ml) 3 times a day; 1-2 years: 7.5 mg (2.5 ml) 2 times a day. Do not use the medicine for more than 4-5 days without medical consultation. In patients with severely impaired hepatic function or with renal impairment, the dose should be halved, and the duration of treatment should not exceed 4-5 days. The syrup should be taken during meals.
(C)
